Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: A partially-blind randomised placebo-controlled study

Vaccine

Volumn 31, Issue 48, 2013, Pages 5745-5753

  Denny, Lynette ^a   Hendricks, Bronwyn ^a   Gordon, Chivaugn ^a   Thomas, Florence ^b   Hezareh, Marjan ^b   Dobbelaere, Kurt ^b   Durand, Christelle ^b   Hervé, Caroline ^b   Descamps, Dominique ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GSK   (Belgium)

Author keywords

HPV vaccination; HPV 16 18 AS04 adjuvanted vaccine; Human immunodeficiency virus (HIV); Human papillomavirus (HPV); Immunogenicity; Safety

Indexed keywords

ANTIGEN; PLACEBO; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADULT; ALLERGIC RHINITIS; ANTIBODY TITER; ARTICLE; BACTERIAL PNEUMONIA; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; LOBAR PNEUMONIA; LYMPHOCYTE COUNT; MIGRAINE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VIRUS LOAD;

ACCORDING-TO-PROTOCOL; ANTIGEN-PRESENTING CELL; ANTIRETROVIRAL THERAPY; APC; ART; ATP; BARC; BIO ANALYTICAL RESEARCH CORPORATION; CI; CONFIDENCE INTERVAL; ELISA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GEOMETRIC MEAN ANTIBODY TITRE; GMT; HIV; HPV; HPV VACCINATION; HPV-16/18 AS04-ADJUVANTED VACCINE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS (HIV); HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS (HPV); IDMC; IMMUNOGENICITY; INDEPENDENT DATA MONITORING COMMITTEE; MONOPHOSPHORYL LIPID A; MPL; NEW-ONSET CHRONIC DISEASE; NOCD; PMTCT; PREVENTING MOTHER-TO-CHILD TRANSMISSION OF HIV; SAE; SAFETY; SERIOUS ADVERSE EVENT; TOTAL VACCINATED COHORT; TVC; WHO; WORLD HEALTH ORGANISATION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HIV; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SINGLE-BLIND METHOD; SOUTH AFRICA; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 84886947596     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.032     Document Type: Article

References (30)

1. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
4. de Sanjose S., Quint W.G.V., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
5. Palefsky J.M., Minkoff H., Kalish L.A., Levine A., Sacks H.S., Garcia P., et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999, 91:226-236.
6. Denny L., Boa R., Williamson A.L., Allan B., Hardie D., Ress S., et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women. Obstet Gynecol 2008, 111:1380-1387.
7. Kahesa C., Mwaiselage J., Wabinga H.R., Ngoma T., Kalyango J.N., Karamagi C.A. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: the need for dual screening. BMC Public Health 2008, 8:262.
8. Singh D.K., Anastos K., Hoover D.R., Burk R.D., Shi Q., Ngendahayo L., et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis 2009, 199:1851-1861.
9. Adjorlolo-Johnson G., Unger E.R., Boni-Ouattara E., Touré-Coulibaly K., Maurice C., Vernon S.D., et al. Assessing the relationship between HIV infection and cervical cancer in Cote d'Ivoire: a case-control study. BMC Infect Dis 2010, 10:242.
10. Auvert B., Lissouba P., Cutler E., Zarca K., Puren A., Taljaard D. Association of oncogenic and nononcogenic human papillomavirus with HIV incidence. J Acquir Immune Defic Syndr 2010, 53:111-116.
11. UNAIDS Report on the Global AIDS Epidemic 2010. [accessed 11.7.12]. http://www.unaids.org/globalreport/Global_report.htm.
12. Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer 2006, 6:135.
13. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
14. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367:1247-1255.
15. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
16. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
17. GlaxoSmithKline Vaccine HPV-007 Study Group Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
18. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
19. Wheeler C.M., Castellsagué X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
20. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization, 2007.
21. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. World Health Organization, 2006.
22. Provincial Administration Western Cape. Antiretroviral Treatment Protocol. Version 2, April 2004.
23. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccine 2008, 4:425-434.
24. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccine 2011, 7:1343-1358.
25. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
26. van den Berg R., van Hoogstraten I., van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009, 11:157-164.
27. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
28. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant, Past experiences and new directions. Pharm Biotechnol 1995, 6:495-524.
29. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2:219-229.
30. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B-cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 2006, 24:5937-5949.